 |
48 Diseases |  |
10 Trials |
|
10 Trials |  |
386 News |  |
| «1234 |
- | stavudine / generics
Clinical, Journal: Engrailed homeoprotein blocks degeneration in adult dopaminergic neurons through LINE-1 repression. (Pubmed Central) - Apr 19, 2019
Similarly, DNA damage and cell death, induced by an acute oxidative stress applied to embryonic midbrain neurons in culture or to adult midbrain dopaminergic neurons in vivo, are accompanied by enhanced LINE-1 expression. Reduction of LINE-1 activity through (i) direct transcriptional repression by Engrailed, (ii) a siRNA directed against LINE-1, (iii) the nucleoside analogue reverse transcriptase inhibitor stavudine, and (iv) viral Piwil1 expression, protects against oxidative stress in vitro and in vivo We thus propose that LINE-1 overexpression triggers oxidative stress-induced DNA strand breaks and that an Engrailed adult function is to protect mesencephalic dopaminergic neurons through the repression of LINE-1 expression.
- ritonavir / Generic mfg.
Primary genotype testing and antiretroviral-resistant mutations among people living with HIV () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1104;
PIs continue to be an option for ART initiation. Primary genotype testing should be enhanced to guide therapy for treatment-naïve people living with HIV and detect potential emerging resistance, especially if low adherence to medications is expected.
- | Epivir (lamivudine) / ViiV Healthcare
Clinical, Observational data, Journal: Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study. (Pubmed Central) - Mar 27, 2019
The number of patients who changed ARV drug in our resource constrained setting present a challenge to the restricted treatment choices that we currently own. Less toxic and better-tolerated HIV treatment options should be available and used more frequently.
- | Prezista (darunavir) / J&J, zidovudine / Generic mfg.
Journal: Metabolic health across the body mass index spectrum in HIV-Infected and HIV-Uninfected Men. (Pubmed Central) - Jul 12, 2018
Metabolically healthy obesity prevalence does not differ by HIV serostatus. However, among nonobese men, HIV infection is associated with lower metabolic health prevalence, with associations between lack of metabolic health and darunavir and thymidine analog nucleoside reverse transcriptase inhibitor exposure observed.
- ||||||| stavudine / Generic mfg., tenofovir disoproxil fumarate / Generic mfg., zidovudine / Generic mfg.
Trial completion: Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children (clinicaltrials.gov) - Oct 6, 2017
P3, N=97, Completed, Sponsor: Gilead Sciences
However, among nonobese men, HIV infection is associated with lower metabolic health prevalence, with associations between lack of metabolic health and darunavir and thymidine analog nucleoside reverse transcriptase inhibitor exposure observed. Active, not recruiting --> Completed
- | stavudine / Generic mfg.
Journal: Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected with HIV in Early Life. (Pubmed Central) - Sep 22, 2017
Subclinical markers of renal dysfunction were increased in HIV-infected young adults and associated with TDF exposure, whereas lower bone density was associated with didanosine and stavudine exposure. The tendency for improvement in markers of bone health over time and the availability of less toxic ARV alternatives may herald improvements in renal and bone health for perinatally infected patients in adulthood.
- | stavudine / Generic mfg., zidovudine / Generic mfg., abacavir / Generic mfg.
Journal: Insulin Resistance and Markers of Inflammation in HIV-Infected Ugandan Children in the CHAPAS 3 Trial. (Pubmed Central) - Sep 21, 2017
The tendency for improvement in markers of bone health over time and the availability of less toxic ARV alternatives may herald improvements in renal and bone health for perinatally infected patients in adulthood. In ART-naive Ugandan children, HOMA-IR changed significantly after 48 weeks of ART and correlated with monocyte activation.
- | Invirase (saquinavir) / Roche, Viracept (nelfinavir) / ViiV Healthcare, Roche
Phase classification: A Prospective Cohort of Children With HIV Infection (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=1000, Recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
In ART-naive Ugandan children, HOMA-IR changed significantly after 48 weeks of ART and correlated with monocyte activation. Phase classification: P4 --> P=N/A
- || stavudine / Generic mfg., tenofovir disoproxil fumarate / Generic mfg., lamivudine / Generic mfg.
New P3 trial, Combination therapy, Head-to-Head: D4T: Dose Optimisation of Stavudine for the Treatment of HIV Infection (clinicaltrials.gov) - Feb 2, 2016
P3, N=1077, Completed, Sponsor: Willem Daniel Francois Venter
- | NN1213 / Novo Nordisk
Trial completion, Discordant: Preventing Sexual Transmission of HIV With Anti-HIV Drugs (clinicaltrials.gov) - Aug 13, 2015
P3, N=3500, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- | stavudine / Generic mfg., ribavirin / Generic mfg., zidovudine / Generic mfg.
Trial completion: Effects of Ribavirin on Zidovudine or Stavudine (clinicaltrials.gov) - May 17, 2015
P=N/A, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Nov 24, 2014
P4, N=68, Completed, Sponsor: Tufts University
No longer recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: When to Start Anti-HIV Drugs in Patients With Opportunistic Infections (clinicaltrials.gov) - Oct 15, 2014
P4, N=283, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed No longer recruiting --> Completed
- | Aptivus (tipranavir) / Boehringer Ingelheim
New P2 trial: Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir (clinicaltrials.gov) - Sep 28, 2014
P2, N=18, Completed, Sponsor: Boehringer Ingelheim
- stavudine / Generic mfg.
Trial completion, Trial primary completion date: Epidermal Nerve Fiber Density, Fat and Mitochondrial Parameters in Thai HIV+ Patients on d4T and HIV- Patients (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=113, Completed, Sponsor: South East Asia Research Collaboration with Hawaii
No longer recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2012 --> Nov 2012
- Invirase (saquinavir) / Roche, Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change, Trial primary completion date: A Prospective Cohort of Children With HIV Infection (clinicaltrials.gov) - Aug 21, 2014
P4, N=1000, Recruiting, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Recruiting --> Completed | Trial primary completion date: May 2012 --> Nov 2012 N=200 --> 1000 | Trial primary completion date: Dec 2013 --> Dec 2020
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion date, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - May 6, 2014
P4, N=70, Recruiting, Sponsor: Tufts University
N=200 --> 1000 | Trial primary completion date: Dec 2013 --> Dec 2020 Trial completion date: Jun 2014 --> Aug 2014
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial primary completion date, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - May 6, 2014
P4, N=70, Recruiting, Sponsor: Tufts University
Trial completion date: Jun 2014 --> Aug 2014 Trial primary completion date: Mar 2014 --> Aug 2014
- | efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients (clinicaltrials.gov) - Feb 22, 2014
P3, N=775, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2014 --> Aug 2014 Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation (clinicaltrials.gov) - Feb 22, 2014
P2, N=402, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| NN1213 / Novo Nordisk
Trial completion: Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients (clinicaltrials.gov) - Feb 19, 2014
P2, N=55, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: A Study of HIV-Disease Development in Aging (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| stavudine / Generic mfg.
Trial completion, Combination therapy: Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients (clinicaltrials.gov) - Feb 19, 2014
P3, N=730, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||| Crixivan (indinavir sulfate) / Merck (MSD)
Trial completion: A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=200, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- | stavudine / Generic mfg.
Trial completion: A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection. (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=40, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- stavudine / Generic mfg.
Trial completion: A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion: A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- || stavudine / Generic mfg.
Trial completion: A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex (clinicaltrials.gov) - Feb 19, 2014
P3, N=20, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| didanosine / Generic mfg.
Trial completion: Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI) (clinicaltrials.gov) - Feb 19, 2014
P3, N=120, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- stavudine / Generic mfg., didanosine / Generic mfg.
Trial completion, Combination therapy: A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| Crixivan (indinavir sulfate) / Merck (MSD)
Trial completion: A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=200, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, NN1213 / Novo Nordisk
Trial completion: A Study to Compare Two Different Anti-HIV Drug Regimens (clinicaltrials.gov) - Feb 19, 2014
P2, N=120, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- stavudine / Generic mfg., lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Crixivan (indinavir sulfate) / Merck (MSD)
Trial completion, IO biomarker: A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection (clinicaltrials.gov) - Sep 3, 2013
P3, N=165, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||||||| Trial completion, Combination therapy: Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. (clinicaltrials.gov) - Jun 20, 2013
P3, N=180, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, Metastases: Antiretroviral Therapy for Advanced HIV Disease in South Africa (clinicaltrials.gov) - Mar 3, 2013
P4, N=1771, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed N=2800 --> 1771
- stavudine / Generic mfg., zidovudine / Generic mfg.
Enrollment open, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Dec 16, 2012
P4, N=70, Recruiting, Sponsor: Tufts University
N=2800 --> 1771 Not yet recruiting --> Recruiting
- | stavudine / Generic mfg., zidovudine / Generic mfg.
New P4 trial, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Sep 24, 2012
P4, N=70, Recruiting, Sponsor: Tufts University
- New P4 trial: Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients (clinicaltrials.gov) - May 16, 2012
P4, N=60, Terminated, Sponsor: University of Witwatersrand, South Africa
- stavudine / Generic mfg., zidovudine / Generic mfg.
Enrollment change, Adverse events: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine (clinicaltrials.gov) - May 14, 2012
P2, N=3, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
Not yet recruiting --> Recruiting N=20 --> 3
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion, Adverse events: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine (clinicaltrials.gov) - May 14, 2012
P2, N=3, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
N=20 --> 3 Recruiting --> Completed
- stavudine / Generic mfg., didanosine / Generic mfg., ritonavir / Generic mfg.
Enrollment change: A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells (clinicaltrials.gov) - May 7, 2012
P1/2, N=46, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=16 --> 46
- hydroxyurea / Generic mfg.
Enrollment change: Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection (clinicaltrials.gov) - Mar 25, 2012
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=16 --> 46 N=252 --> 0
- stavudine / Generic mfg.
Trial completion, Combination therapy: A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants (clinicaltrials.gov) - Feb 13, 2012
P1/2, N=26, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=252 --> 0 Active, not recruiting --> Completed